.jpg "Accuray Inc (NASDAQ: ARAY)")
In a report released yesterday, Anthony Petrone from Jefferies reiterated a Buy rating on Accuray Inc (NASDAQ: ARAY), with a price target of $6. The company’s shares closed yesterday at $3.88.
According to TipRanks.com, Petrone is a 4-star analyst with an average return of 16.2% and a 55.7% success rate. Petrone covers the Healthcare sector, focusing on stocks such as Varex Imaging Corporation, Varian Medical Systems, and Haemonetics Corp.
Currently, the analyst consensus on Accuray Inc is a Moderate Buy with an average price target of $6.
See today’s analyst top recommended stocks >>
Based on Accuray Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $946K. In comparison, last year the company had a GAAP net loss of $5.26 million.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. Last month, Alaleh Nouri, the SVP, General Counsel & of ARAY sold 8,559 shares for a total of $34,835.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Accuray, Inc. is a radiation oncology company. It develops, manufactures and sells precise, innovative treatment solutions, which include cyberKnife and tomo therapy systems, which are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy.
